‹ Latest Events
Novavax, Inc.
Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines - NVAX
Published October 12, 2026
Event
Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines - NVAX
Read full article on zacks.com →About Novavax, Inc.
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
$11.26
-1.56%
More from NVAX
Exchange Mix — Recent NVAX Events
NASDAQ
100%
NYSE
0%
AMEX
0%
OTC
0%